Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ...
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...
Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.